๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical trials of botulinum toxin in the treatment of spasticity

โœ Scribed by David M. Simpson


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
101 KB
Volume
20
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Treatment of spasticity with botulinum t
โœ David M. Simpson ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 75 KB ๐Ÿ‘ 2 views

Restoration of neurological function following injury to the nervous system has long been the aim of neuroscientists and clinicians. The central nervous system (CNS) has proven to be an elusive target for restorative treatment. Although neuroprotective agents show promise, once injury to the brain o

Treatment of spasticity with botulinum t
โœ G. E. Borodic; R. Ferrante; A. W. Wiegner; R. R. Young ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB
Dosing, administration, and a treatment
โœ Mitchell F. Brin ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 481 KB ๐Ÿ‘ 1 views

Botulinum toxin type A (BTX-A) has been shown to be a safe and effective treatment for focal or segmental muscle overactivity, including spasticity. Local injections of BTX-A are particularly valuable in relieving focal spasticity around a joint or a series of joints. When integrated into an overall

A clinical overview of treatment decisio
โœ Mark E. Gormley; Jr.; Christopher F. O'Brien; Stuart A. Yablon ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 214 KB ๐Ÿ‘ 1 views

Spasticity from an upper motor neuron syndrome may cause a variety of symptoms that interfere with function. Decisions regarding spasticity treatment are influenced by the chronicity, severity, and distribution of the spasticity; the locus of injury; the presence and severity of co-morbidities; the